Comparative in vitro activity of ceftaroline and comparator agents against nosocomial Gram-negative and Gram-positive clinically significant bacterial isolates from patients in a teaching hospital in Kuwait

Affiliations


Abstract

The objective was to test the in vitro activities of ceftaroline and comparator agents against clinical isolates of Gram-negative and Gram-positive bacteria. Isolates were identified with VITEK II. Susceptibility testing was with E test. A total of 1264 isolates were tested. Compared to other cephalosporins, ceftaroline demonstrated excellent in vitro activities (MIC90, ≤0.5 mg/L) against Escherichia coli, Salmonella spp. and Haemophilus influenzae. When matched with the comparator cephalosporins, ceftaroline demonstrated the greatest activity against methicillin-susceptible Staphylococcus aureus (MSSA), with MIC90 of 0.25 mg/L. Ceftaroline's MIC90s against both community-associated methicillin-resistant S. aureus (MRSA) and hospital-acquired MRSA were 0.5 and 1 mg/L, respectively. Major discrepancies were noted between E test and disc diffusion tests for ceftaroline only against 16 Gram-negative and 16 Gram-positive isolates. Ceftaroline demonstrated an excellent in vitro activity against the majority of clinically significant Gram-negative and Gram-positive isolates obtained from proven cases of bacterial infections.

Keywords: Bacteria; Ceftaroline; Gram-negative; Gram-positive; Kuwait; Susceptibility.


Similar articles

In vitro activity of ceftaroline-avibactam against gram-negative and gram-positive pathogens isolated from patients in Canadian hospitals from 2010 to 2012: results from the CANWARD surveillance study.

Karlowsky JA, Adam HJ, Baxter MR, Lagacé-Wiens PR, Walkty AJ, Hoban DJ, Zhanel GG.Antimicrob Agents Chemother. 2013 Nov;57(11):5600-11. doi: 10.1128/AAC.01485-13. Epub 2013 Aug 26.PMID: 23979759 Free PMC article.

In vitro activity of ceftaroline against gram-positive and gram-negative pathogens isolated from patients in Canadian hospitals in 2009.

Karlowsky JA, Adam HJ, Decorby MR, Lagacé-Wiens PR, Hoban DJ, Zhanel GG.Antimicrob Agents Chemother. 2011 Jun;55(6):2837-46. doi: 10.1128/AAC.01787-10. Epub 2011 Mar 14.PMID: 21402844 Free PMC article.

Antimicrobial activity of ceftobiprole and comparator agents when tested against contemporary Gram-positive and -negative organisms collected from Europe (2015).

Pfaller MA, Flamm RK, Duncan LR, Streit JM, Castanheira M, Sader HS.Diagn Microbiol Infect Dis. 2018 May;91(1):77-84. doi: 10.1016/j.diagmicrobio.2017.12.020. Epub 2018 Jan 3.PMID: 29395713

Ceftaroline: a new broad-spectrum cephalosporin.

Lim L, Sutton E, Brown J.Am J Health Syst Pharm. 2011 Mar 15;68(6):491-8. doi: 10.2146/ajhp100181.PMID: 21378297 Review.

Ceftaroline fosamil: a new broad-spectrum cephalosporin.

Laudano JB.J Antimicrob Chemother. 2011 Apr;66 Suppl 3:iii11-8. doi: 10.1093/jac/dkr095.PMID: 21482565 Review.


Cited by

Evaluation of the in vitro activity of ceftaroline, ceftazidime/avibactam and comparator antimicrobial agents against clinical isolates from paediatric patients in Kuwait: ATLAS data 2012-19.

Al-Sweih N, Jamal W, Mokaddas E, Habashy N, Kurdi A, Mohamed N.JAC Antimicrob Resist. 2021 Dec 6;3(4):dlab159. doi: 10.1093/jacamr/dlab159. eCollection 2021 Dec.PMID: 36479234 Free PMC article.


KMEL References